Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MultiCloneSeq

Financiado

Cerrado

Single-Clone Multi-omics Sequencing for Cancer Diagnosis

Cancer led to one in six death worlds wildly. By nature, cancer is characterized by abnormal and uncontrolled cellular growth caused primarily by genetic mutations. Despite of the high cellular heterogeneity, only a small number o... ver más

31/03/2025

THE HEBREW UNIVERS...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-26

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

THE HEBREW UNIVERSITY OF JER...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CancerMultiOm Deciphering Cancer Heterogeneity and Drug resistance using S... 2M€ Cerrado

ONCOTRACK OncoTrack Methods for systematic next generation oncology... 31M€ Cerrado

ONCOTRACK OncoTrack - Methods for systematic next generation oncology... 31M€ Cerrado

SIOMICS SIngle cell multi OMICs approach to study intra tumour heter... 195K€ Cerrado

EpiResist Exposing hidden targets of drug resistance in cancer by mapp... 1M€ Cerrado

CancerFLCloneSeq Clone-based full-length RNA-seq for early diagnosis of cance... 150K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2023-09-26
Fecha Fin: 2025-03-31

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer led to one in six death worlds wildly. By nature, cancer is characterized by abnormal and uncontrolled cellular growth caused primarily by genetic mutations. Despite of the high cellular heterogeneity, only a small number of somatic mutations shown to be directly associated with tumorigenesis, hence driving cancer growth. The first hurdle in the cancer diagnosis is to identify these rare populations that have the potential to develop drug resistance. A second hurdle is to be able to associate mutations in the genetic level to the RNA expression level, which will improve the chance of pinpointing a specific mutation with the relevant activity. Therefore, it is of crucial importance to develop a single-cell multi-omics sequencing tool to simultaneously study the heterogeneity of expression and DNA-based regulation of cancer-associated genes. Recently, several multi-omics tools have emerged that allow for the interrogation of both gene expression and open chromatin regions. However, there are some notable limitations constrain the capability and applicability of these tools: 1) The expensive and disposable apparatuses and reagents of these methods is extremely expensive, and thus limits their extensive application and potential as a diagnosis tool; 2) The transcriptome derived from all these technologies only captures the 3 ' RNA termini of polyadenylated transcripts. It excludes the capture of non-polyadenylated transcripts which plays a vital role in cancer development, and the interrogation of somatic mutation from full length RNA. (3) The low input of single-cell material leads to the sparse data. To overcome these hurdles, our novel technology is based on three methods that we have developed leveraging the power of microfluidics: 1. single-clone sequencing, 2.Full-length RNA, and 3. A cost efffective open chromatin extraction method. MultiCloneSeq will be the first method providing low-cost and full-scale multiomic profiling with high resolution.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores